Publications by authors named "S Christenson"
Asthma is a heterogeneous disease with variable presentation and characteristics. There is a critical need to identify underlying molecular endotypes of asthma. We performed the largest transcriptomic analysis of 808 bronchial epithelial cell (BEC) samples across 11 independent cohorts, including 3 cohorts from the Severe Asthma Research Program (SARP).
View Article and Find Full Text PDFBackground: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We aimed to assess the efficacy and safety of tezepelumab in patients with moderate to very severe COPD despite receiving triple inhaled therapy.
Methods: COURSE was a double-blind, randomised, placebo-controlled, phase 2a trial across 90 sites in ten countries in Asia, Europe, and North America.
Background: Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, reduced exacerbations and improved lung function in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation in the phase 3 BOREAS trial.
Objective: To assess clinical outcomes in patients from BOREAS by emphysema status.
Methods: Patients with COPD and type 2 inflammation (screening blood eosinophils ≥300 cells/μL) on maximal inhaled therapy were randomized to add-on dupilumab 300 mg or placebo every 2 weeks for 52 weeks.
Article Synopsis
- Exacerbations in COPD are serious events that can worsen lung function and impair quality of life, highlighting the need for effective medication to manage them.
- Ensifentrine is a new drug that works as a dual inhibitor to reduce inflammation and open airways, and the study aimed to evaluate its effectiveness in reducing COPD exacerbation rates.
- The analysis from two phase 3 trials involving nearly 1,000 patients showed that ensifentrine significantly reduced both the frequency and risk of severe COPD exacerbations compared to a placebo across various patient subgroups.
Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.
Chronic Obstr Pulm Dis
September 2024
Article Synopsis
- The SPIROMICS Study of Early COPD Progression (SOURCE) aims to investigate the biological reasons behind early-stage COPD in younger individuals who smoke, addressing a gap in current medical knowledge that hinders treatment development.
- The study plans to enroll 649 participants aged 30-55 with a history of smoking, alongside 40 never-smoker controls, to collect comprehensive health data and analyze potential mechanisms of disease progression.
- SOURCE seeks to use advanced imaging and biospecimen collection methods over three years to enhance understanding of COPD and contribute to better prevention and treatment strategies.